4/24
01:00 am
ipsey
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
Low
Report
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
4/23
05:28 pm
ipsey
Ipsen en Skyhawk Therapeutics kondigen samenwerking aan op het gebied van onderzoek naar RNA-targeting bij zeldzame neurologische aandoeningen
Low
Report
Ipsen en Skyhawk Therapeutics kondigen samenwerking aan op het gebied van onderzoek naar RNA-targeting bij zeldzame neurologische aandoeningen
4/22
01:00 am
ipsey
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Medium
Report
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
4/22
01:00 am
ipsey
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Medium
Report
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
4/22
01:00 am
ipsey
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Medium
Report
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
4/2
07:00 am
ipsey
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen
Medium
Report
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen
4/2
01:00 am
ipsey
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
Medium
Report
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
2/13
04:08 pm
ipsey
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
Low
Report
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
2/8
12:58 am
ipsey
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
Low
Report
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024